Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Limited is engaged in the marketing of pharmaceutical products in domestic and international markets. The company is also engaged in distribution of pharmaceutical products through third-party distribution network.[1]It is a part of the Trident Texofab Group
- Market Cap ₹ 360 Cr.
- Current Price ₹ 313
- High / Low ₹ 339 / 136
- Stock P/E 60.7
- Book Value ₹ 46.0
- Dividend Yield 0.00 %
- ROCE 14.7 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -1.98%
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
21.77 | 31.69 | 44.63 | |
19.05 | 25.42 | 36.40 | |
Operating Profit | 2.72 | 6.27 | 8.23 |
OPM % | 12.49% | 19.79% | 18.44% |
0.60 | 1.16 | 2.08 | |
Interest | 0.13 | 0.48 | 0.65 |
Depreciation | 0.20 | 0.36 | 0.97 |
Profit before tax | 2.99 | 6.59 | 8.69 |
Tax % | -32.11% | 8.50% | 31.65% |
3.95 | 6.02 | 5.94 | |
EPS in Rs | 4.94 | 5.24 | 5.51 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 41% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -2% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 67% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Equity Capital | 8.00 | 11.50 | 11.50 |
Reserves | -3.22 | 34.14 | 41.40 |
2.46 | 7.69 | 18.41 | |
6.60 | 9.25 | 15.77 | |
Total Liabilities | 13.84 | 62.58 | 87.08 |
1.43 | 3.16 | 20.90 | |
CWIP | 0.00 | 4.83 | 4.03 |
Investments | 0.00 | 3.34 | 3.77 |
12.41 | 51.25 | 58.38 | |
Total Assets | 13.84 | 62.58 | 87.08 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
-0.21 | -19.00 | 2.23 | |
-0.45 | -9.69 | -20.36 | |
0.80 | 42.28 | 11.01 | |
Net Cash Flow | 0.14 | 13.60 | -7.13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Debtor Days | 83.33 | 139.25 | 109.92 |
Inventory Days | 95.16 | 129.36 | 156.45 |
Days Payable | 134.15 | 86.78 | 93.64 |
Cash Conversion Cycle | 44.34 | 181.83 | 172.72 |
Working Capital Days | 66.56 | 319.39 | 250.83 |
ROCE % | 22.79% | 14.66% |
Documents
Announcements
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
23 Sep - Disclosure of share acquisition under SEBI regulations.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Sep
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
23 Sep - Disclosure of substantial acquisition of shares.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 21 Sep
-
Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011
21 Sep - Disclosure of substantial acquisition of shares by promoter.
Business categories[1]
1. Ethical marketing of pharmaceutical formulation & products in International Markets through a third-party distribution network and sales force under its own brand
2. Getting approved formulations manufactured through Contract Manufacturers, Source & Supply of Generic Pharma formulation and medicines in Domestic and International Market.
The company is working on Asset-light third-party contract manufacturing model.